biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Time Warp

<< Previous

Bullboard Posts

Next >>

Comment by GPIAnchoron Nov 06, 2022 6:18pm

162 Views

Post# 35077700

RE:Time Warp

If you want to take it back even further, the patents that WR Partners licensed from UBC were originally financed by both Synapse Technologies Inc. and UBC in the period from 1992-2002. The US Biotech firm BIOMARIN then bought Synapse in 2002. At some point in time after that the patents were returned to UBC and then became available to WR Partners. I suspect that the development of the peptide was a useful means to extend patent life as well as decrease manufacturing costs and improve transport characteristics.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario